Drug Profile
Zoledronic acid - Axsome Therapeutics
Alternative Names: AXS 02; Disodium (1-Hydroxy-2-(1H-Imidazol-1-yl)-1- Phosphonoethyl)Phosphonic Acid - Axsome Therapeutics; Disodium zoledronate tetrahydrate - Axsome Therapeutics; Oral zoledronateLatest Information Update: 20 Oct 2021
Price :
$50
*
At a glance
- Originator ANTECIP BIOVENTURES
- Developer Axsome Therapeutics
- Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Back pain
- Discontinued Pain
Most Recent Events
- 09 Mar 2021 Phase-II development for Back pain (chronic low back pain with modic changes) is ongoing in Finland (EudraCT2015-000751-25)
- 11 Mar 2019 Axsome Therapeutics in-licenses patent portfolio from Antecip
- 11 Mar 2019 Axsome Therapeutics has patent protection for zoledronic acid in USA and other countries